X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs VENUS REMEDIES - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA VENUS REMEDIES TORRENT PHARMA/
VENUS REMEDIES
 
P/E (TTM) x 34.5 -517.5 - View Chart
P/BV x 5.2 0.1 3,546.5% View Chart
Dividend Yield % 1.0 0.0 -  

Financials

 TORRENT PHARMA   VENUS REMEDIES
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-17
VENUS REMEDIES
Mar-17
TORRENT PHARMA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs1,768143 1,238.0%   
Low Rs1,18665 1,824.0%   
Sales per share (Unadj.) Rs346.1324.2 106.8%  
Earnings per share (Unadj.) Rs55.26.4 860.7%  
Cash flow per share (Unadj.) Rs73.340.6 180.7%  
Dividends per share (Unadj.) Rs14.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs257.1366.0 70.2%  
Shares outstanding (eoy) m169.2212.34 1,371.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.30.3 1,331.2%   
Avg P/E ratio x26.816.2 165.1%  
P/CF ratio (eoy) x20.12.6 786.7%  
Price / Book Value ratio x5.70.3 2,023.3%  
Dividend payout %25.40-   
Avg Mkt Cap Rs m249,8871,282 19,490.1%   
No. of employees `00011.80.9 1,304.7%   
Total wages/salary Rs m9,934251 3,957.8%   
Avg. sales/employee Rs Th4,971.54,430.1 112.2%   
Avg. wages/employee Rs Th843.2278.0 303.4%   
Avg. net profit/employee Rs Th792.487.6 904.7%   
INCOME DATA
Net Sales Rs m58,5694,000 1,464.1%  
Other income Rs m2,23323 9,837.0%   
Total revenues Rs m60,8024,023 1,511.3%   
Gross profit Rs m13,773785 1,755.2%  
Depreciation Rs m3,069422 728.0%   
Interest Rs m2,056344 598.1%   
Profit before tax Rs m10,88142 25,845.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,545-37 -4,175.9%   
Profit after tax Rs m9,33679 11,802.5%  
Gross profit margin %23.519.6 119.9%  
Effective tax rate %14.2-87.9 -16.2%   
Net profit margin %15.92.0 806.1%  
BALANCE SHEET DATA
Current assets Rs m53,8412,606 2,065.9%   
Current liabilities Rs m31,6121,980 1,596.3%   
Net working cap to sales %38.015.6 242.6%  
Current ratio x1.71.3 129.4%  
Inventory Days Days97128 75.7%  
Debtors Days Days8443 194.1%  
Net fixed assets Rs m42,0795,353 786.0%   
Share capital Rs m846123 685.7%   
"Free" reserves Rs m42,6554,393 971.1%   
Net worth Rs m43,5014,516 963.3%   
Long term debt Rs m22,4081,618 1,384.8%   
Total assets Rs m101,2508,291 1,221.2%  
Interest coverage x6.31.1 560.7%   
Debt to equity ratio x0.50.4 143.8%  
Sales to assets ratio x0.60.5 119.9%   
Return on assets %11.35.1 220.6%  
Return on equity %21.51.8 1,225.3%  
Return on capital %19.66.3 312.1%  
Exports to sales %00-   
Imports to sales %018.4 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA736 0.0%   
Fx inflow Rs m20,0660-   
Fx outflow Rs m5,304736 720.4%   
Net fx Rs m14,762-736 -2,004.9%   
CASH FLOW
From Operations Rs m10,127997 1,015.5%  
From Investments Rs m-7,869-461 1,705.9%  
From Financial Activity Rs m-1,918-571 335.9%  
Net Cashflow Rs m212-35 -602.6%  

Share Holding

Indian Promoters % 71.5 32.9 217.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 0.2 3,900.0%  
FIIs % 12.6 0.6 2,172.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 66.4 13.3%  
Shareholders   26,511 20,121 131.8%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   WYETH LTD  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  SHASUN PHARMA  PFIZER  

Compare TORRENT PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Extends Losses; Pharma Stocks Top Losers(Closing)

After opening the day in red share markets in India witnessed negative trading activity throughout the day, and ended well below the dotted line.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Looking Beyond the Colourful Prism of This Airline Company(Sector Info)

May 10, 2018

Can Interglobe Aviation Safely Fly Out of Turbulence?

HDFC Prudence Fund Now HDFC Balanced Advantage Fund - Time To Sell?(Outside View)

May 9, 2018

PersonalFN provides detail analysis on HDFC Balanced Advantage Fund (erstwhile HDFC Prudence Fund and HDFC Growth Fund).

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


May 21, 2018 03:35 PM

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS